Survival and Prognostic Factors in Small Cell Lung Cancer Patients in Turkey

Authors

  • F. Ece Pulmonary Oncology Clinic, SSK Sureyyapasa Chest and Cardiovascular Diseases Hospital, Istanbul, Turkey
  • N. Erdal Pulmonary Oncology Clinic, SSK Sureyyapasa Chest and Cardiovascular Diseases Hospital, Istanbul, Turkey
  • S. Arinc Pulmonary Oncology Clinic, SSK Sureyyapasa Chest and Cardiovascular Diseases Hospital, Istanbul, Turkey
Abstract:

Background: Small cell lung cancer (SCLC) is a highly aggressive tumor. Objective: To evaluate the survival and time to progression of patients with SCLC admitted to a chest disease center in Istanbul, Turkey. Methods: Based on the reports of a pulmonary oncology clinic, data regarding performance status (PS), clinical stage of disease, treatment, time to progression and survival of 67 patients with SCLC diagnosed between 1999 and 2002, were examined. Results: The median survival time of these patients was 10 months (range: 4-21 months).  The median time to progression was 7.2 months; 7.2 months for limited stage and 7.1 for extended stage.  Complete and partial responses with first line chemotherapy were achieved in 19 (28%) and 29 (43%) patients, respectively.  30 patients (45%) received thorax radiotherapy (RT).  Survival in patients who had thoracic RT was significantly longer than others (p=0.018).  26 of all patients (39%) showed progression within 6 months after first line chemotherapy.  19 patients (28%) received second line chemotherapy with complete response achieved in 2 patients. Conclusion: Main factors affecting survival and length of time to progression were PS, stage of disease, and cigarette smoking.  Patients with good PS, limited disease, and less smoking had superior survival times and longer time to progression. 

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

survival and prognostic factors in small cell lung cancer patients in turkey

background: small cell lung cancer (sclc) is a highly aggressive tumor.   objective: to evaluate the survival and time to progression of patients with sclc admitted to a chest disease center in istanbul, turkey.   methods: based on the reports of a pulmonary oncology clinic, data regarding performance status (ps), clinical stage of disease, treatment, time to progression and survival of 67 pati...

full text

The Effect of Time-dependent Prognostic Factors on Survival of Non-Small Cell Lung Cancer using Bayesian Extended Cox Model

  Abstract Background: Lung cancer is one of the most common cancers around the world. The aim of this study was to use Extended Cox Model (ECM) with Bayesian approach to survey the behavior of potential time-varying prognostic factors of Non-small cell lung cancer. Materials and Methods: Survival status of all 190 patients diagnosed with Non-Small Cell lung cancer referring to hospitals in ...

full text

Prognostic Factors and Survival in Non-Small Cell Lung Cancer Patients Treated with Chemoradiotherapy

BACKGROUND According to the literature, performance status, stage-tumor dimension and nodal status, weight loss, were the most important prognostic factors for survival in patients with locally advanced non-small cell lung cancer. AIM To evaluate the treatment results and the prognostic variables in our patients treated with sequential and concurrent chemoradiotherapy. MATERIAL AND METHODS ...

full text

Expression of Epidermal Growth Factor Receptor and the association with Demographic and Prognostic Factors in Patients with Non-small Cell Lung Cancer

Introduction: Growth, proliferation, survival, and differentiation are the prominent characteristics of cells, which are affected by cancer. Epidermal growth factor receptor (EGFR) plays a pivotal role in the effective control of these features. Given the significance of EGFR signaling pathway in non-small cell lung cancer (NSCLC), EGFR expression is influential on these cell characteristics. I...

full text

Effects of prognostic factors and treatment on survival in advanced non-small cell lung cancer.

In this study, 304 stage III-B and IV non-small cell lung cancer (NSCLC) cases diagnosed and followed up in our hospital between January 2000 and December 2002 are retrospectively analysed. The effects of demographic, clinical, laboratory findings and different therapeutic modalities on survival were investigated. Of the cases, 31 (10.2%) were women, 273 (89.8%) were men and mean age was 60.59 ...

full text

Survival and prognostic factors in resected cN2-pN0 non-small cell lung cancer.

This study retrospectively examined the records of patients with clinical N2 (cN2) stage non-small cell lung cancer (NSCLC) who were surgically treated but who actually had pathologic N0 (pN0) stage disease. From 1982 to 1997, 94 patients with cN2 NSCLC underwent surgery. Forty-five patients proved to have pN0 disease, with an overall 5-year survival rate of 67.3%. According to the Cox model, v...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 29  issue 1

pages  9- 13

publication date 2015-10-04

By following a journal you will be notified via email when a new issue of this journal is published.

Keywords

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023